Faculty of Economics and Management Science, Leipzig University, Chair for Health Economics and Management, Leipzig, Germany.
Scientific Institute for Health Economics and Health System Research (WIG2 GmbH), Markt 8, 04109, Leipzig, Germany.
BMC Health Serv Res. 2023 Apr 17;23(1):369. doi: 10.1186/s12913-023-09287-w.
With its digital health application (DiGA)-system, Germany is considered one of Europe's pioneers in the field of evidence-based digital health. Incorporating DiGA into standard medical care must be based on evidence-based success factors; however, a comprehensive overview of the evidence required of scientific studies for their approval is lacking.
The study aims to, (1) identify specific requirements defined by the Federal Institute for Drugs and Medical Devices (German: Bundesinstitut für Arzneimittel- und Medizinprodukte; BfArM) to design adequate studies, proving a positive healthcare effect, and (2) to assess the evidence given for applications permanently listed in the DiGA directory.
A multi-step approach was used: (1) identification of the evidence requirements for applications permanently listed in the DiGA directory, (2) identification of the evidence available supporting them.
All DiGA permanently listed in the DiGA directory (13 applications) are included in the formal analysis. Most DiGA addressed mental health (n = 7), and can be prescribed for one or two indications (n = 10). All permanently listed DiGA have demonstrated their positive healthcare effect through a medical benefit, and most of them provide evidence for one defined primary endpoint. All DiGA manufacturers conducted a randomized controlled trial.
It is striking that- although patient-relevant structural and procedural improvements show high potential for improving care, especially in terms of processes - all DiGA have provided a positive care effect via a medical benefit. Although BfArM accepts study designs with a lower level of evidence for the proof of a positive healthcare effect, all manufacturers conducted a study with a high level of evidence.
The results of this analysis indicate that permanently listed DiGA meet higher standards than required by the guideline.
德国凭借其数字健康应用(DiGA)系统,被认为是欧洲在循证数字健康领域的先驱之一。将 DiGA 纳入标准医疗必须基于循证成功因素;然而,对于获得批准所需的科学研究的综合证据概述却缺乏。
本研究旨在:(1)确定联邦药品和医疗器械研究所(German: Bundesinstitut für Arzneimittel- und Medizinprodukte; BfArM)为设计能证明有积极的医疗效果的充分研究而规定的具体要求,以及(2)评估在 DiGA 目录中永久列出的应用程序所提供的证据。
采用多步骤方法:(1)确定在 DiGA 目录中永久列出的应用程序的证据要求,(2)确定支持这些要求的可用证据。
所有在 DiGA 目录中永久列出的 DiGA(13 个应用程序)都包含在正式分析中。大多数 DiGA 用于治疗心理健康问题(n=7),可以针对一个或两个适应症进行处方(n=10)。所有永久列出的 DiGA 都通过医疗效益证明了其积极的医疗效果,其中大多数都提供了一个明确的主要终点的证据。所有 DiGA 制造商都进行了随机对照试验。
尽管患者相关的结构和程序改进具有提高护理质量的巨大潜力,尤其是在流程方面,但所有 DiGA 都是通过医疗效益来提供积极的护理效果,这一点令人震惊。尽管 BfArM 接受用于证明积极医疗效果的证据水平较低的研究设计,但所有制造商都进行了具有较高证据水平的研究。
本分析结果表明,永久列出的 DiGA 符合高于指南要求的标准。